Arsenal Biosciences, a leading cell therapy company specializing in solid tumor treatment, has secured $325 million in Series C funding. The oversubscribed round attracted new investors like ARCH Venture Partners and Milky Way Investments Group. Existing investors, including the Parker Institute for Cancer Immunotherapy and SoftBank Vision Fund 2, also participated.
ArsenalBio’s proprietary T-cell engineering technology showcases promise in early clinical trials and preclinical studies. The company plans to use the funds to advance its lead programs and expand its pipeline of therapeutic options for solid tumor cancers. The investment will also drive innovation in identifying new cell therapies.
“This investment empowers us to continue our development roadmap, scale our manufacturing capabilities, and pursue groundbreaking advancements in T-cell medicine,” said ArsenalBio CEO Ken Drazan. The company’s robust pipeline includes therapies for ovarian, kidney, and prostate cancers developed in collaboration with Bristol-Myers Squibb Company. ArsenalBio recently initiated a Phase 1/2 clinical trial for its second T cell product candidate, AB-2100, for clear-cell renal cell carcinoma, receiving Fast Track designation from the U.S. Food and Drug Administration.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
